Fortrea Holdings: An Insight into its Clinical Outsourcing Growth & Other Major Drivers!

Fortrea’s financial results for the first quarter of 2025 presented a mixed picture of performance and challenges as it navigates a transformation phase post-spinoff. The company reported revenues of $651.3 million, a slight decline of 1.6% compared to the previous year. This decrease was attributed primarily to the variable nature of late-stage clinical service fee new business wins, compounded by a slowdown in the backlog burn rate. However, the company noted slight growth in its Phase I clinical pharmacology business offsetting the broader revenue decline.